Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03126630 · OUTCOME

Phase I - Recommended Phase 2 Dose of Ametumab Ravtansine With Combination of Pembrolizumab

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma · Source last updated 2026-04-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/kg IV
Interval / dispersion
Not reported
Time frame
Up to 2 years

What was measured

All patients that have received any amount of the combination anetumab ravtansine and pembrolizumab will be evaluable for toxicity. Please note this is different from the definition of evaluable for dose-limiting toxicity (DLT) where patients who cannot complete the planned dose due to reasons other than toxicity will be replaced.

Groups in this outcome

Phase 1 Cohort: Anetumab Ravtansine & MK-3475

Phase 1 Cohort: Anetumab ravtansine \& MK-3475

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 1 Cohort: Anetumab Ravtansine & MK-347513

Reported measurements

Source class 1
Values in mg/kg IV · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase 1 Cohort: Anetumab Ravtansine & MK-34756.5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        6.5
denoms
  1. counts
    1. group Id
      OG000
      value
      13
    units
    Participants
description
All patients that have received any amount of the combination anetumab ravtansine and pembrolizumab will be evaluable for toxicity. Please note this is different from the definition of evaluable for dose-limiting toxicity (DLT) where patients who cannot complete the planned dose due to reasons other than toxicity will be replaced.
groups
  1. description
    Phase 1 Cohort: Anetumab ravtansine \& MK-3475
    id
    OG000
    title
    Phase 1 Cohort: Anetumab Ravtansine & MK-3475
param Type
NUMBER
reporting Status
POSTED
time Frame
Up to 2 years
title
Phase I - Recommended Phase 2 Dose of Ametumab Ravtansine With Combination of Pembrolizumab
type
PRIMARY
unit Of Measure
mg/kg IV

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice